Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Goldenwell BiotechGWLL -9.09%31 Equity-to-Asset is -13.72 as of Jun. 2026. GuruFocus rates GWLL with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 1,995 Consumer Packaged Goods companies, Goldenwell Biotech ranks worse than 99.5% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Goldenwell Biotech Equity-to-Asset Related Terms
Goldenwell Biotech Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Goldenwell Biotech's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GWLL vs LFVN, FTLF, CLNN: Equity-to-Asset Comparison
For the Packaged Foods subindustry, Goldenwell Biotech's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Goldenwell Biotech Equity-to-Asset vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Goldenwell Biotech's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Goldenwell Biotech's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Goldenwell Biotech's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Goldenwell Biotech (GWLL) has a Equity-to-Asset of -13.72 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Goldenwell Biotech and its competitors. According to the industry distribution chart, Goldenwell Biotech ranks #1985 out of 1995 companies in the Consumer Packaged Goods industry, placing it in the top 99.5%.
Is Goldenwell Biotech's Equity-to-Asset too high?
Goldenwell Biotech's current Equity-to-Asset is -13.72. Based on the distribution chart, Goldenwell Biotech ranks #1985 out of 1995 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Goldenwell Biotech has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Goldenwell Biotech's Equity-to-Asset compare to LFVN and FTLF?
According to the Consumer Packaged Goods industry distribution chart, Goldenwell Biotech ranks #1985 out of 1995 companies for Equity-to-Asset. This places Goldenwell Biotech in the lower half of its industry. The industry median Equity-to-Asset is 0.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Consumer Packaged Goods company?
The median Equity-to-Asset among Consumer Packaged Goods companies is 0.55, based on 1,995 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Goldenwell Biotech and its competitors. For the Consumer Packaged Goods industry, the median Equity-to-Asset is 0.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Goldenwell Biotech's current Equity-to-Asset is -13.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Goldenwell Biotech stock overvalued right now?
Goldenwell Biotech (GWLL) has a current Equity-to-Asset of -13.72. The current Equity-to-Asset is -13.72. Goldenwell Biotech's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Goldenwell Biotech (GWLL), the current Equity-to-Asset is -13.72 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Goldenwell Biotech Inc is engaged in the research and development, production, and sales of healthcare and supplement products. Its products comprise JI MAI - Bovine Cardiac Vascular Active Peptide, Double Proline AG - 3D Active Collagen Peptide, Cartilage Peptide - Type II collagen peptide, and Sugar Master.
31GF Score
Get the complete analysis for GWLL
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GWLL has been successfully added to your 
